Lv1
90 积分 2023-04-21 加入
Bispecific Anti-OX40/5T4 Antibodies for Cancer Treatment
2天前
已关闭
4-1BB and OX40 Dual Costimulation Synergistically Stimulate Primary Specific CD8 T Cells for Robust Effector Function
3天前
已完结
First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma
7天前
已完结
BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity
8天前
已完结
Facilitating Selection with Artificial Intelligence-Based Glypican-3 Expression Quantification in Patients with Solid Tumors
8天前
已完结
Facilitating Selection with Artificial Intelligence-Based Glypican-3 Expression Quantification in Patients with Solid Tumors
8天前
已完结
Facilitating Selection with Artificial Intelligence-Based Glypican-3 Expression Quantification in Patients with Solid Tumors
8天前
已完结
First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma
9天前
已完结
A Novel Designed Anti–PD-L1/OX40 Bispecific Antibody Augments Both Peripheral and Tumor-Associated Immune Responses for Boosting Antitumor Immunity
10天前
已完结
OX40, PD‐1 and CTLA‐4 are selectively expressed on tumor‐infiltrating T cells in head and neck cancer
15天前
已完结
皖公网安备34019202002308
